HOMEPRODUCTSSERVICESCOMPANYCONTACTFAQResearchDictionaryPharmaMobileSign Up FREE or Login

The role of intensive AML-specific therapy in treatment of children with RAEB and RAEB-t.

Abstract
To determine the role of intensive chemotherapy and allogeneic bone marrow transplantation (BMT) in treatment of refractory anemia with excess of blasts (RAEB) or RAEB-t (in transformation), the outcome of 37 consecutive children, 12 with RAEB and 25 with RAEB-t, diagnosed between 1985 and 1995 was analyzed. Fourteen patients received intensive chemotherapy according to the AML-BFM protocols 83, 87, or 93 (group 1). Seven patients were treated less intensively with the 6-week consolidation phase as induction (group 2). Allogeneic BMT was performed in 10 children of group 1 and 2 after, and in eight (group 3) without prior chemotherapy. Eight children received minimal or no chemotherapy (group 4). Of 21 children (groups 1 and 2) 17 (81%) achieved complete or partial remission after chemotherapy, 12 of them (10 of group 1) remained in remission, eight after BMT. Five-year survival in 29 children treated intensively (groups 1-3) was 46%, SE 12%. Two of the other eight children (group 4) remained alive, one after spontaneous remission. Outcome after BMT was related to the blast count in the bone marrow prior to BMT. None of 10 children (including two with minimal or no chemotherapy) with < or = 12% blasts before BMT relapsed, in contrast to five of eight patients with a higher blast count (P log rank 0.02). We conclude that a substantial number of children with RAEB or RAEB-t can achieve remission with intensive AML-specific chemotherapy. In patients responding to intensive chemotherapy an increase in long-term survival after allogeneic BMT can be expected.
AuthorsU Creutzig, C Bender-Götze, J Ritter, M Zimmermann, B Stollmann-Gibbels, D Körholz, C Niemeyer
JournalLeukemia (Leukemia) Vol. 12 Issue 5 Pg. 652-9 (May 1998) ISSN: 0887-6924 [Print] ENGLAND
PMID9593261 (Publication Type: Journal Article)
Chemical References
  • Cytarabine
  • Etoposide
  • Mitoxantrone
  • Daunorubicin
Topics
  • Adolescent
  • Anemia, Refractory, with Excess of Blasts (drug therapy, pathology, therapy)
  • Antineoplastic Combined Chemotherapy Protocols (adverse effects, therapeutic use)
  • Bone Marrow Transplantation (adverse effects)
  • Cell Transformation, Neoplastic
  • Child
  • Child, Preschool
  • Combined Modality Therapy
  • Cytarabine (administration & dosage)
  • Daunorubicin (administration & dosage)
  • Etoposide (administration & dosage)
  • Female
  • Humans
  • Infant
  • Male
  • Mitoxantrone (administration & dosage)
  • Remission Induction

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research network!


Choose Username:
Email:
Password:
Verify Password: